Wire · operational-macro
When Phase 3 Fails Because of Trial Design, Someone Missed a Signal Months Earlier
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 October 2026 · Fusion42 review
A Phase 3 trial for AstraZeneca's hypophosphatasia drug failed due to poor trial design that missed an early signal, highlighting the operational gap where clinical operations fail to pressure-test trial endpoint sensitivity during feasibility and site activation in rare disease studies.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.
◆ ◆ The Wire takeaway
You lose trial credibility and patient trust if your feasibility process skips endpoint sensitivity checks. Add an enrichment review before site activation to save millions and keep your rare disease programme on track.
◆ Coverage
1 source · 12 Oct 2026
◆ Related on Wire
◆ Topics